Recent Blog Articles
Gun violence: A long-lasting toll on children and teens
Adult female acne: Why it happens and the emotional toll
Talking to your doctor about your LGBTQ+ sex life
Untangling grief: Living beyond a great loss
Thunderstorm asthma: Bad weather, allergies, and asthma attacks
Heart problems and the heat: What to know and do
I’m too young to have Alzheimer’s disease or dementia, right?
Period equity: What it is and why it matters
Back pain: Will treatment for the mind, body—or both—help?
Colon cancer screening decisions: What’s the best option and when?
Prostate Health Archive
Prostate cancer lives as it is born: slow-growing and benign or fast-growing and dangerous
In many men diagnosed with prostate cancer, the cancer cells grow so slowly that they never break free of the gland, spread to distant sites, and pose a serious risk to health and longevity. Instead of embarking on immediate treatment, a growing number of men choose active surveillance, in which doctors monitor low-risk cancers closely and consider treatment only when the disease appears to make threatening moves toward growing and spreading. A new Harvard study shows that the aggressiveness of prostate cancer at diagnosis remains stable over time for most men. If confirmed, then prompt treatment can be reserved for the cancers most likely to pose a threat, while men with slow-growing, benign prostate cancer—which is unlikely to cause problems in a man’s lifetime—can reasonably choose active surveillance.
High intake of omega-3 fats linked to increased prostate cancer risk
The omega-3 fats in fish have been linked to all sorts of health benefits, including protection against prostate cancer. But for the second time in two years, researchers have found a link between high levels of omega-3 fats in the blood and prostate cancer. Researchers at the Fred Hutchinson Cancer Center in Seattle men with high levels of omega-3 fats were 43% more likely to have been diagnosed with prostate cancer than men with low levels. The finding were published online in the Journal of the National Cancer Institute.
New treatment option for prostate cancer that has spread to the bones
The radioactive element radium has been used to treat cancer since soon after its discovery in 1898 by Marie Curie and her husband, Pierre. And it’s still finding new uses—a recently approved form of radium, radium-223 (Xofigo), is now being used to treat prostate cancer that has spread to the bones. Researchers say that Xofigo addresses “an unmet need” in men with this type of prostate cancer, since current therapies don’t work very well against it.
Genetic testing to guide prostate removal: too soon to know if it helps
Is it possible for a gene test to identify whether a prostate that’s healthy today is sure to develop cancer down the road? And should results of such a test be the basis for removing a seemingly healthy prostate gland? Those are questions raised by recent press reports of a British man who had his prostate gland removed because he carried a faulty gene called BRCA2.
Healthy fats may fight early-stage prostate cancer
Each year, nearly a quarter of a million American men learn they have prostate cancer. Most are diagnosed with early-stage cancer that has not spread beyond the prostate gland. Traditional treatments include surgery, radiation therapy, and a “watch and wait” strategy called active surveillance. A new study published online this week in JAMA Internal Medicine indicates that diet may be an important add-on. The study, part of the ongoing Harvard-based Health Professionals Follow-up Study, suggests that eating more foods that deliver healthy vegetable oils can help fight the second leading cause of cancer death in men. Earlier studies have implicated the traditional Western diet, which is relatively high in red meat and other sources of animal fats, with a higher risk for developing prostate cancer in the first place, while eating more vegetable oils and vegetable protein may help prevent it.
Harvard expert urges caution for use of new prostate cancer test
The FDA has approved a new kind of PSA test for prostate cancer that its maker claims can help doctors do a better job of telling the difference between prostate cancer and less worrisome conditions such as prostate infection or benign prostate enlargement. The test, called the Prostate Health Index (PHI), should become available in the U.S. later this summer. The PHI combines measurements of three kinds of prostate specific antigen (PSA), a protein produced by the prostate gland. In theory, the combination could help reduce the number of men who undergo prostate biopsies when their PSA levels are slightly above normal, in the 4 to 10 nanogram per milliliter range. But doctors must take care not to allow use of the PHI test to worsen the existing overdiagnosis and overtreatment of low-risk cancers, according to Dr. Marc B. Garnick, an expert in prostate cancer at Harvard Medical School and editor in chief of HarvardProstateKnowledge.org.
PSA screening for prostate cancer: a doctor’s perspective
Yesterday’s announcement that men should not get routine PSA tests to check for hidden prostate cancer is sure to spark controversy for months to come. But the U.S. Preventive Services Task Force (USPSTF) made the right decision. On the surface, rejecting the use of a simple blood test that can detect cancer in its early and still-treatable stage sounds foolish. Cynics have been saying it is the handiwork of a group concerned more about health-care rationing and cutting costs than about health. The decision is wise, not foolish, and will improve men’s health, not harm it. The word “cancer” usually brings to mind images of a fast-growing cluster of cells that, without aggressive treatment, will invade other parts of the body, damage health, and potentially kill. That certainly describes many cancers. But not most prostate cancers. Most of the time, prostate cancer is sloth-like. It tends to grow slowly and remain confined to the prostate gland, with many men never knowing during their entire lives that a cancer was present. These slow-growing prostate cancers cause no symptoms and never threaten health or longevity. That means many men with prostate “cancer” never need treatment.
Panel says “no” to routine prostate cancer testing
A simple blood test to check seemingly healthy men for hidden prostate cancer does more harm than good and shouldn’t be part of routine medical care. That’s the long-awaited final recommendation from the United States Preventive Services Task Force (USPSTF), published today in Annals of Internal Medicine. About half of men over age 40 get this test as part of a regular checkup. It measures the amount of a protein called prostate-specific antigen, or PSA, in the bloodstream. An above-normal PSA level can signal hidden prostate cancer. But it can also be a sign of prostate infection, an enlarged prostate, and other problems. Hunting for hidden disease in the absence of any outward signs or symptoms is called screening. The task force says that for every 1,000 men who have routine PSA tests, 0 to 1 deaths from prostate cancer will be prevented. But that is offset by 3 serious cardiovascular deaths due to treatment, along with 47 men who will live with treatment-related erectile dysfunction or incontinence.
Buffett’s prostate cancer: poor decisions
Warren Buffett may be the second richest man in America, but he appears to be getting the poorest medical advice. Buffett announced to Berkshire Hathaway shareholders last week that he has early stage prostate cancer that “is not remotely life-threatening or even debilitating in any meaningful way.” If Buffett’s cancer had been detected because he […]
New study won’t end debate on PSA test for prostate cancer
A large study from Europe does little to resolve the controversy over whether men should have a simple blood test to look for hidden prostate cancer. In the study, the number of deaths over the course of the 11-year study were the same in men tested for prostate-specific antigen (PSA) and in men who didn’t have the test. Because prostate cancer usually grows very slowly, detecting it in an older man generally isn’t helpful. Some men live with the side effects of treatment—notably impotence and incontinence—for a cancer that would have had no effect on the length or quality of their lives. This study and others suggest that we rethink the widespread use of PSA testing, especially the yearly screening that is common in the United States.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!